Palisade Bio to Showcase PALI-2108 Prodrug’s Fibrostenotic Crohn’s Potential at June 9 Symposium
PALI•At the New York Academy of Sciences symposium on June 9, 2026, Palisade Bio’s CMO Dr. Mitchell Jones will present on PALI-2108, a locally bioactivated PDE4 inhibitor prodrug targeting fibrostenotic Crohn’s disease. Preclinical findings show selective ileum and colon activation with positive Phase 1 results prior to Phase 2 studies.
1. Symposium Presentation
On June 9, 2026, Palisade Bio’s President and Chief Medical Officer, Dr. Mitchell Jones, will deliver a presentation at the New York Academy of Sciences symposium on Molecular Pathways and Cellular Players in the Resolution of Organ Fibrosis. The talk, titled “Locally Bioactivated PDE4 Inhibitor Prodrug for the Treatment of Fibrostenotic Crohn’s Disease (FSCD),” will cover the biological underpinnings of intestinal fibrosis and the therapeutic rationale for a localized PDE4 inhibitor prodrug approach.
2. PALI-2108 Prodrug Mechanism
PALI-2108 is designed as a once-daily oral PDE4 inhibitor prodrug that undergoes bioactivation specifically in the terminal ileum and colon, the primary sites of disease in fibrostenotic Crohn’s disease. The targeted activation aims to concentrate therapeutic levels of the active PDE4 inhibitor at fibrotic lesions while minimizing systemic exposure to reduce off-target effects and improve tolerability compared to traditional PDE4 inhibitors.
3. Clinical Development Progress
Preclinical studies have demonstrated PALI-2108’s ability to modulate key inflammatory and fibrotic pathways in intestinal fibrosis models, supporting its mechanism of action. The molecule has achieved positive safety and tolerability results in a Phase 1a and two Phase 1b trials in ulcerative colitis and fibrostenotic Crohn’s disease. Palisade Bio is now preparing to initiate Phase 2 clinical trials in both UC and Crohn’s disease patients to evaluate efficacy and dosing regimens.
